ITIH4 is a predictor for coronary thrombus in coronary arteriography patients

References

• Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118:145–156. doi:10.1161/CIRCRESAHA.115.306656
   PubMed Web of Science ®Google Scholar
• Arbel Y, Shacham Y, Ziv-Baran T, et al. Higher neutrophil/lymphocyte ratio is related to lower ejection fraction and higher long-term all-cause mortality in ST-elevation myocardial infarction patients. Can J Cardiol. 2014;30:1177–1182. doi:10.1016/j.cjca.2014.05.010
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–2505. doi:10.1056/NEJMoa1912388
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Fan J, Watanabe T. Atherosclerosis: known and unknown. Pathol Int. 2022;72:151–160. doi:10.1111/pin.13202
   PubMed Web of Science ®Google Scholar
• Crea F, Libby P. Acute coronary syndromes: the way forward from mechanisms to precision treatment. Circulation. 2017;136:1155–1166. doi:10.1161/CIRCULATIONAHA.117.029870
   PubMed Web of Science ®Google Scholar
• Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203–214. doi:10.1016/s0021-9150(03)00012-1
   PubMed Web of Science ®Google Scholar
• Díaz-Chirón L, Negral L, Megido L, et al. Relationship between exposure to sulphur dioxide air pollution, white cell inflammatory biomarkers and enzymatic infarct size in patients with ST-segment elevation acute coronary syndromes. Eur Cardiol. 2021;16:e50. doi:10.15420/ecr.2021.37
   PubMed Web of Science ®Google Scholar
• Osada A, Matsumoto I, Mikami N, et al. Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 in arthritic joints and its potential effect in the neutrophil migration. Clin Exp Immunol. 2021;203:385–399. doi:10.1111/cei.13556
   PubMed Web of Science ®Google Scholar
• Pihl R, Jensen RK, Poulsen EC, et al. ITIH4 acts as a protease inhibitor by a novel inhibitory mechanism. Sci Adv. 2021;7:eaba7381. doi:10.1126/sciadv.aba7381
   PubMed Web of Science ®Google Scholar
• Larsen JB, Pihl R, Aggerbeck MA, et al. Inter-α-inhibitor heavy chain H4 and sepsis-related coagulation disturbances: another link between innate immunity and coagulation. Res Pract Thromb Haemost. 2023;7:100078. doi:10.1016/j.rpth.2023.100078
   PubMed Web of Science ®Google Scholar
• Huo Y, Lai Y, Feng Q, Wang Q, Li J. Serum ITIH4 in coronary heart disease: a potential anti-inflammatory biomarker related to stenosis degree and risk of major adverse cardiovascular events. Biomark Med. 2022;16:1279–1288. doi:10.2217/bmm-2022-0673
   PubMed Web of Science ®Google Scholar
• Xu H, Shang Q, Chen H, et al. ITIH4: a new potential biomarker of “toxin syndrome” in coronary heart disease patient identified with proteomic method. Evid Based Complement Alternat Med. 2013;2013:360149. doi:10.1155/2013/360149
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang X. Cardiovascular Group, Geriatrics Branch of Chinese Medical Association. Chinese expert consensus on antithrombotic management of high-risk elderly patients with chronic coronary syndrome. Aging Med (Milton). 2023;6:4–24. doi:10.1002/agm2.12234
   PubMedGoogle Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407–477. doi:10.1093/eurheartj/ehz425
   PubMed Web of Science ®Google Scholar
• Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–1367. doi:10.1093/eurheartj/ehaa575
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315. doi:10.1093/eurheartj/ehv320
   PubMed Web of Science ®Google Scholar
• Soler L, García N, Unzueta A, Piñeiro M, Álava MA, Lampreave F. Purification and determination of C-reactive protein and inter-α-trypsin inhibitor heavy chain 4 in dogs after major surgery through generation of specific antibodies. Vet Immunol Immunopathol. 2016;179:26–31. doi:10.1016/j.vetimm.2016.07.010
   PubMed Web of Science ®Google Scholar
• Ma Y, Li R, Wang J, et al. ITIH4, as an inflammation biomarker, mainly increases in bacterial bloodstream infection. Cytokine. 2021;138:155377. doi:10.1016/j.cyto.2020.155377
   PubMed Web of Science ®Google Scholar
• Kashyap RS, Nayak AR, Deshpande PS, et al. Inter-alpha-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke. Clin Chim Acta. 2009;402:160–163. doi:10.1016/j.cca.2009.01.009
   PubMed Web of Science ®Google Scholar
• Nayak AR, Kashyap RS, Kabra D, Purohit HJ, Taori GM, Daginawala HF. Time course of inflammatory cytokines in acute ischemic stroke patients and their relation to inter-alfa trypsin inhibitor heavy chain 4 and outcome. Ann Indian Acad Neurol. 2012;15:181–185. doi:10.4103/0972-2327.99707
   PubMed Web of Science ®Google Scholar
• Dimitroglou Y, Aggeli C, Theofilis P, et al. Novel anti-inflammatory therapies in coronary artery disease and acute coronary syndromes. Life (Basel). 2023;13:1669. doi:10.3390/life13081669
   PubMed Web of Science ®Google Scholar
• Liberale L, Montecucco F, Schwarz L, Lüscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res. 2021;117:411–422. doi:10.1093/cvr/cvaa211
   PubMed Web of Science ®Google Scholar
• Miceli G, Basso MG, Rizzo G, Pintus C, Tuttolomondo A. The role of the coagulation system in peripheral arterial disease: interactions with the arterial wall and its vascular microenvironment and implications for rational therapies. Int J Mol Sci. 2022;23:14914. doi:10.3390/ijms232314914
   PubMed Web of Science ®Google Scholar
• Puylaert P, Zurek M, Rayner KJ, De Meyer GRY, Martinet W. Regulated necrosis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2022;42:1283–1306. doi:10.1161/ATVBAHA.122.318177
   PubMed Web of Science ®Google Scholar
• Jenny L, Dobó J, Gál P, Schroeder V. MASP-1 induced clotting–the first model of prothrombin activation by MASP-1. PLOS ONE. 2022;42:1283–1306. doi:10.1161/ATVBAHA.122.318177
   Google Scholar
• Sendama W, Musgrave KM. Decision-making with d-dimer in the diagnosis of pulmonary embolism. Am J Med. 2018;131:1438–1443. doi:10.1016/j.amjmed.2018.08.006
   PubMed Web of Science ®Google Scholar
• Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: a review. JAMA. 2022;328:1336–1345. doi:10.1001/jama.2022.16815
   PubMed Web of Science ®Google Scholar